TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32970697
Drug: Daily self-administered
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-administered vaginal progesterone (VP)
Study: 33866656
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment received
Study: 37380728
Drug: Dapagliflozin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin plus basal‐bolus insulin (DAPA group)
Study: 37380728
Drug: Basal‐bolus insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal‐bolus insulin alone (INSULIN group)
Study: 34197281
Drug: V-01 vaccine
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-01 vaccine (10, 25, and 50 µg)
Study: 34197281
Drug: V-01 vaccine
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-01 vaccine (10 µg) subgroup and elderly participants
Study: 32369298
Drug: Topical spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray of papaverine on harvested LIMA
Study: 32369298
Drug: Perivascular injection
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perivascular injection of papaverine
Study: 36681255
Drug: Revefenacin 175
Normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revefenacin 175 μg
Study: 32158738
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment with biopsychosocial perceived etiology
Study: 32158738
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with biopsychosocial perceived etiology
Study: 32158738
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment with biomedical perceived etiology
Study: 32158738
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with biomedical perceived etiology
Study: 32158738
Drug: Treatment information
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment information wording matching perceived etiology
Study: 36216984
Drug: Parent–Child Interaction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent–Child Interaction Therapy‐Emotion Development (PCIT‐ED)
Study: 33967202
Drug: Gemcitabine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine maintenance therapy
Study: 32888121
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control with antiarrhythmic drugs (AADs)
Study: 32785213
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg BNT162b1
Study: 32815416
Drug: Therapeutic-dose anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose anticoagulation with low-molecular-weight heparin or unfractionated heparin
Study: 35923359
Drug: Short-term oxygen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oxygen therapy (STOT)
Study: 35923359
Drug: Short-term oxygen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oxygen therapy (STOT) for more than one month or repeated prescriptions
Study: 32024447
Drug: Internet self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet self-help blended with face-to-face therapy
Study: 35442766
Drug: Tislelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (200 mg every 3 weeks)
Study: 34973513
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Study: 32404437
Drug: Intramuscular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gentamicin
Study: 32045103
Drug: PRGF‐gel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRGF‐gel treatment
Study: 35293287
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus brivaracetam 100 mg
Study: 35293287
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion brivaracetam 100 mg
Study: 35293287
Drug: Oral reference
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral reference tablet brivaracetam 100 mg
Study: 33606908
Drug: iGlarLixi once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iGlarLixi once daily
Study: 33606908
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 twice daily
Study: 35844458
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 7% sevoflurane and intravenous infusion of remifentanil
Study: 35844458
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 7% sevoflurane
Study: 32854761
Drug: Guideline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline therapy plus TCMR (acupressure therapy and Liu Zi Jue Qigong exercises)
Study: 32854761
Drug: Guideline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline therapy (control group)
Study: 33798466
Drug: Volanesorsen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volanesorsen (300 mg subcutaneously once a week for 26 weeks, then every 2 weeks)
Study: 33798466
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 mL subcutaneously once a week for 26 weeks, then every 2 weeks)
Study: 33137579
Drug: SPEEDI intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPEEDI intervention (10 therapy sessions until 3 months' corrected age, 5 hospital sessions and 5 home-based sessions)
Study: 36484441
Drug: 10-μg TAK-426
Normalized name: immunoglobulin G, human 10 % Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-μg TAK-426 vaccine
Study: 33858553
Drug: Empiric antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotics for MRSA infection
Study: 33858553
Drug: Non-MRSA antibiotics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-MRSA antibiotics
Study: 34614379
Drug: Liquid MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid MenACWY-CRM vaccine presentation stored for approximately 24 months
Study: 34614379
Drug: Liquid MenACWY-CRM
Normalized name: Meningococcal oligosaccharide (MenACWY), (MenB), PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid MenACWY-CRM vaccine presentation stored for approximately 30 months
Study: 34614379
Drug: Licensed lyophilized/liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed lyophilized/liquid MenACWY-CRM vaccine presentation
Study: 33887722
Drug: 1-Step COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-Step COVID-19 Test for total antibodies
Study: 34778734
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) PEP (400/100 mg) twice daily for 5 days
Study: 35987857
Drug: Expert assessment
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expert assessment of shoulder impairments followed by an individualised treatment plan
Study: 35648426
Drug: EGCG solution
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG solution (660 μmol/L)
Study: 34365061
Drug: Propolis (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (500 mg/day)
Study: 32128877
Drug: Low-dose SIM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SIM (200 mg)
Study: 32128877
Drug: High-dose SIM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SIM (1200 mg)
Study: 34453358
Drug: guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 200 mg
Study: 34453358
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg (after placebo)
Study: 34453358
Drug: guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 200 mg (after placebo)
Study: 35875346
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets (500 mg, 2 tab/day)
Study: 32182098
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus the codesigned education video delivered via a handheld tablet device at discharge
Study: 34628152
Drug: Multimodal program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal program including mindfulness-based practices, expressive arts, and EMDR group treatment
Study: 32575124
Drug: Tocilizumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (400 mg dose)
Study: 37232393
Drug: Non-statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-statin therapy
Study: 35533197
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid at 1.65 mL/kg/h
Study: 35533197
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid at 1.65 mL/kg/h (in patients without diabetes)
Study: 35533197
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.125 M L‐glutamic acid
Study: 32191400
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU twice daily
Study: 35045999
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy alone (HFNO or standard oxygen)
Study: 34731916
Drug: Postoperative Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative Hb < 10 g/dl
Study: 32557305
Drug: Risk-based quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-based quality management approach in clinical trials with combination products
Study: 32557305
Drug: Combination products
Normalized name: Other cardiac combination products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination products in clinical trials
Study: 33196289
Drug: Paraffin bath
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paraffin bath therapy
Study: 33606023
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy with comprehensive EPC service referral
Study: 33606023
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic therapy without EPC
Study: 33048260
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (1 g of amoxicillin, twice daily for 7 days)
Study: 32997386
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (control)
Study: 35914262
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (CBT) with interoceptive exposure
Study: 32154636
Drug: Gilteritinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib (120 mg once daily)
Study: 37644897
Drug: THC 20
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 20 mg
Study: 33326356
Drug: ALIS+GBT (590
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALIS+GBT (590 mg once-daily for 12 months)
Study: 34325483
Drug: Withdrawal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal and early preventive medication (W+P)
Study: 34325483
Drug: Preventives with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventives with potential withdrawal therapy after 6 months (P+pW)
Study: 34325483
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effect (all groups combined)
Study: 33221559
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 gm if body weight <90 kg, 1.5 g if body weight >90 kg)
Study: 33221559
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml of distilled water in 15 ml of 5% dextrose)
Study: 33053279
Drug: BNT162b2 (lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Study: 33053279
Drug: BNT162b1 (lipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b1 (lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidate)
Study: 35907513
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg by mouth 3 times a day for 30-36 months
Study: 32948827
Drug: bissap tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: bissap tablets (2 × 375 mg/day)
Study: 32948827
Drug: bissap brew
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bissap brew (10 g of calyx/day)
Study: 32948827
Drug: kinkeliba tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: kinkeliba tablets (2 × 200 mg/day)
Study: 32948827
Drug: kinkeliba brew
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: kinkeliba brew (10 g of leaves/day)
Study: 32948827
Drug: captopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (2 × 50 mg/day)
Study: 33443933
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered before surgery and at various time points postoperatively.
Study: 33443933
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered before surgery and at various time points postoperatively.
Study: 33443933
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (1g) taken by healthy volunteers.
Study: 35605268
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg and cetylpyridinium chloride 1.00 mg in the form of tablets for resorption
Study: 36404687
Drug: Cetylpyridinium chloride
Normalized name: Cetylpyridinium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Study: 32846782
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dexamethasone (4 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Study: 32846782
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dexamethasone (2 mL) intravenously just after anesthesia and repeated at 24 hours after surgery
Study: 34175463
Drug: Performing rectal
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performing rectal sutures within 8 cm from the anal verge
Study: 33648834
Drug: Sodium 4-phenylbutyrate
Normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium 4-phenylbutyrate (NaPB) high dose (4.3 g/m2) administered pre-breakfast
Study: 33648834
Drug: Sodium 4-phenylbutyrate
Normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium 4-phenylbutyrate (NaPB) low dose (1.4 g/m2) administered pre-breakfast
Study: 33648834
Drug: Sodium 4-phenylbutyrate
Normalized name: 4-phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium 4-phenylbutyrate (NaPB) administered post-breakfast (both doses)
Study: 35863990
Drug: Single CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single CO2 laser treatment
Study: 38828109
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp)
Study: 35831046
Drug: Concurrent consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent consent during in‐person assessment for health data
Study: 35831046
Drug: Concurrent consent
Normalized name: Consensi
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent consent during in‐person assessment for education data
Study: 33010045
Drug: Mentalization‐Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization‐Based Treatment (MBT)
Study: 35284808
Drug: 1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg
Study: 35284808
Drug: 1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg + CpG1018
Study: 35284808
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg
Study: 35284808
Drug: 3 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg + CpG1018
Study: 35284808
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg
Study: 34011035
Drug: Bailing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bailing Capsule (BC) combined with α-ketoacid tablets (KA)
Study: 34011035
Drug: BC-simulation combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-simulation combined with α-ketoacid tablets (KA)
Study: 32921794
Drug: CBD (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (600 mg)
Study: 36164037
Drug: R-CHOP +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP + tafasitamab (12 mg/kg IV, D1, 8, 15)
Study: 36164037
Drug: R-CHOP +
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP + tafasitamab + lenalidomide (25 mg orally, D1-10)
Study: 32989825
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (50 mg/kg−1)
Study: 32989825
Drug: Systemic tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic tranexamic acid (20 mg/kg−1 through cardiopulmonary bypass and another 20 mg/kg−1 after separation)
Study: 34399759
Drug: iStent inject®
Approvals — FDA: no, EMA: no, PMDA: no
Description: iStent inject® + concurrent cataract surgery
Study: 32464421
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera leaves extract (MOLE) at a dose of 40 mg/kg orally daily
Study: 32464421
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and selenium at a dose of 3 ml (4.5 mg sodium selenite and 204 mg vitamin E)/head i.m twice a week for 64 days
Study: 32472001
Drug: Olaparib tablets
Normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablets (300 mg twice daily)
Study: 35598114
Drug: Chloroquine alone
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine alone (600 mg base)
Study: 35598114
Drug: Chloroquine with
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine with azithromycin (500 mg)
Study: 35598114
Drug: Chloroquine with
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine with azithromycin (1,000 mg)
Study: 35598114
Drug: Chloroquine with
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine with azithromycin (1,500 mg)
Study: 32614987
Drug: IncoA intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncoA intradermal injection (100 unit or 1 vial in 6 cc of NSS)
Study: 32614987
Drug: IncoA intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncoA intradermal injection
Study: 33788485
Drug: Thumbtack needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thumbtack needling therapy
Study: 36036107
Drug: Sham-thumbtack needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham-thumbtack needling therapy
Study: 36036107
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (PCA)
Study: 32423457
Drug: Differed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differed treatment program
Study: 33148686
Drug: Dextrose gel
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose gel (buccal 40% dextrose gel)
Study: 32040014
Drug: CYD‐TDV (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV (tetravalent dengue vaccine)
Study: 36070590
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with LED irradiation
Study: 36357085
Drug: TEER plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEER plus guideline-directed medical therapy (GDMT)
Study: 33390654
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (fluticasone)
Study: 38670610
Drug: Oral glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoids
Study: 36303867
Drug: Nomogram including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nomogram including variables such as radiotherapy, primary site surgery, Ann Arbor Stage, chemotherapy, histological subtype, and age at diagnosis.
Study: 34737091
Drug: Lofexidine (alpha-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (alpha-2 adrenergic agonist)
Study: 33533820
Drug: Early therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early therapy (rehabilitative protocol started immediately after the initial evaluation)